Compare Stocks: SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN Astrazeneca	$160.74 -0.7%	$175.98	$145.79 ▼ $212.71	$249.19B	0.26	2.71 million shs	814,308 shs
AZN Astrazeneca	$160.74 -0.7%	$175.98	$145.79 ▼ $212.71	$249.19B	0.26	2.71 million shs	814,308 shs
AZNCF AstraZeneca	$187.10 +0.6%	$187.10	$122.26 ▼ $195.00	N/A	N/A	1,957 shs	N/A
GSK GSK	$51.42 -1.4%	$51.86	$37.80 ▼ $61.69	$103.78B	0.36	4.63 million shs	585,751 shs
GSK GSK	$51.42 -1.4%	$51.86	$37.80 ▼ $61.69	$103.78B	0.36	4.63 million shs	585,751 shs
LLY Eli Lilly and Company	$1,222.54 -0.8%	$1,162.38	$629.40 ▼ $1,249.45	$1.15T	0.51	3.12 million shs	416,676 shs
ON onsemi	$81.69 +2.4%	$99.87	$44.56 ▼ $134.92	$31.87B	2.03	10.69 million shs	957,849 shs
PFE Pfizer	$26.85 -0.8%	$25.05	$23.58 ▼ $28.75	$153.01B	0.34	42.29 million shs	5.90 million shs
SDGR Schrodinger	$19.13 +1.9%	$15.75	$10.94 ▼ $23.02	$1.41B	1.63	1.35 million shs	237,700 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN Astrazeneca	+0.32%	+2.27%	-5.85%	-12.31%	+9.99%
AZN Astrazeneca	+0.32%	+2.27%	-5.85%	-12.31%	+9.99%
AZNCF AstraZeneca	0.00%	0.00%	0.00%	0.00%	+31.97%
GSK GSK	-1.98%	+1.00%	-1.41%	+2.24%	+37.79%
GSK GSK	-1.98%	+1.00%	-1.41%	+2.24%	+37.79%
LLY Eli Lilly and Company	+3.65%	+9.59%	+3.44%	+24.23%	+96.75%
ON onsemi	-1.71%	-0.77%	-16.86%	-23.37%	+67.39%
PFE Pfizer	+1.26%	+7.94%	+11.67%	+4.47%	+10.05%
SDGR Schrodinger	+3.36%	+22.84%	+13.83%	+47.91%	-2.29%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AZN Astrazeneca	$160.74 -0.7%	$175.98	$145.79 ▼ $212.71	$249.19B	0.26	2.71 million shs	814,308 shs
AZN Astrazeneca	$160.74 -0.7%	$175.98	$145.79 ▼ $212.71	$249.19B	0.26	2.71 million shs	814,308 shs
AZNCF AstraZeneca	$187.10 +0.6%	$187.10	$122.26 ▼ $195.00	N/A	N/A	1,957 shs	N/A
GSK GSK	$51.42 -1.4%	$51.86	$37.80 ▼ $61.69	$103.78B	0.36	4.63 million shs	585,751 shs
GSK GSK	$51.42 -1.4%	$51.86	$37.80 ▼ $61.69	$103.78B	0.36	4.63 million shs	585,751 shs
LLY Eli Lilly and Company	$1,222.54 -0.8%	$1,162.38	$629.40 ▼ $1,249.45	$1.15T	0.51	3.12 million shs	416,676 shs
ON onsemi	$81.69 +2.4%	$99.87	$44.56 ▼ $134.92	$31.87B	2.03	10.69 million shs	957,849 shs
PFE Pfizer	$26.85 -0.8%	$25.05	$23.58 ▼ $28.75	$153.01B	0.34	42.29 million shs	5.90 million shs
SDGR Schrodinger	$19.13 +1.9%	$15.75	$10.94 ▼ $23.02	$1.41B	1.63	1.35 million shs	237,700 shs

The 7 Hottest IPO Stories of 2026

MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AZN Astrazeneca	+0.32%	+2.27%	-5.85%	-12.31%	+9.99%
AZN Astrazeneca	+0.32%	+2.27%	-5.85%	-12.31%	+9.99%
AZNCF AstraZeneca	0.00%	0.00%	0.00%	0.00%	+31.97%
GSK GSK	-1.98%	+1.00%	-1.41%	+2.24%	+37.79%
GSK GSK	-1.98%	+1.00%	-1.41%	+2.24%	+37.79%
LLY Eli Lilly and Company	+3.65%	+9.59%	+3.44%	+24.23%	+96.75%
ON onsemi	-1.71%	-0.77%	-16.86%	-23.37%	+67.39%
PFE Pfizer	+1.26%	+7.94%	+11.67%	+4.47%	+10.05%
SDGR Schrodinger	+3.36%	+22.84%	+13.83%	+47.91%	-2.29%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AZN Astrazeneca	2.73	Moderate Buy	$211.00	31.27% Upside
AZN Astrazeneca	2.73	Moderate Buy	$211.00	31.27% Upside
AZNCF AstraZeneca	0.00	N/A	N/A	N/A
GSK GSK	2.10	Hold	$53.00	3.08% Upside
GSK GSK	2.10	Hold	$53.00	3.08% Upside
LLY Eli Lilly and Company	2.87	Moderate Buy	$1,292.18	5.70% Upside
ON onsemi	2.48	Hold	$100.63	23.17% Upside
PFE Pfizer	2.19	Hold	$28.28	5.33% Upside
SDGR Schrodinger	2.33	Hold	$20.25	5.87% Upside

Current Analyst Ratings Breakdown

Latest SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/7/2026	ON onsemi	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (D+) ➝ Hold (C)
8/7/2026	LLY Eli Lilly and Company	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$1,376.00
8/7/2026	PFE Pfizer	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$35.00 ➝ $31.00
8/7/2026	LLY Eli Lilly and Company	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$1,370.00 ➝ $1,376.00
8/6/2026	LLY Eli Lilly and Company	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$1,419.00
8/6/2026	LLY Eli Lilly and Company	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,280.00 ➝ $1,330.00
8/6/2026	LLY Eli Lilly and Company	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$1,400.00
8/6/2026	LLY Eli Lilly and Company	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$1,350.00 ➝ $1,410.00
8/5/2026	ON onsemi	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Hold	$101.00 ➝ $91.00
8/5/2026	ON onsemi	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Neutral	$120.00 ➝ $98.00
8/4/2026	ON onsemi	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$125.00 ➝ $110.00

(Data available from 8/11/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AZN Astrazeneca	$58.74B	4.24	$12.87 per share	12.49	$31.41 per share	5.12
AZN Astrazeneca	$58.74B	4.24	$12.87 per share	12.49	$31.41 per share	5.12
AZNCF AstraZeneca	N/A	N/A	N/A	N/A	N/A	N/A
GSK GSK	$43.07B	2.41	$5.83 per share	8.82	$10.32 per share	4.98
GSK GSK	$43.07B	2.41	$5.83 per share	8.82	$10.32 per share	4.98
LLY Eli Lilly and Company	$65.18B	17.66	$25.92 per share	47.17	$28.07 per share	43.55
ON onsemi	$6.00B	5.30	$4.16 per share	19.63	$19.12 per share	4.27
PFE Pfizer	$62.58B	2.45	$4.41 per share	6.09	$15.26 per share	1.76
SDGR Schrodinger	$255.87M	5.52	N/A	N/A	$4.94 per share	3.87

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AZN Astrazeneca	$10.23B	$6.69	24.02	14.12	1.39	17.02%	31.45%	13.20%	10/30/2026 (Estimated)
AZN Astrazeneca	$10.23B	$6.69	24.02	14.12	1.39	17.02%	31.45%	13.20%	10/30/2026 (Estimated)
AZNCF AstraZeneca	N/A	$0.82	229.29	N/A	N/A	N/A	N/A	N/A	N/A
GSK GSK	$7.54B	$3.20	16.04	10.00	3.04	14.56%	43.23%	11.60%	10/28/2026 (Estimated)
GSK GSK	$7.54B	$3.20	16.04	10.00	3.04	14.56%	43.23%	11.60%	10/28/2026 (Estimated)
LLY Eli Lilly and Company	$20.64B	$29.80	40.96	26.86	1.38	33.53%	97.83%	23.23%	10/29/2026 (Estimated)
ON onsemi	$121M	$1.56	52.47	18.15	0.67	10.17%	14.06%	8.31%	N/A
PFE Pfizer	$7.77B	$0.76	35.32	9.16	N/A	6.80%	19.63%	8.46%	N/A
SDGR Schrodinger	-$103.26M	-$0.74	N/A	N/A	N/A	-20.98%	-16.37%	-8.19%	N/A

Latest SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2026	Q2 2026	LLY Eli Lilly and Company	$6.40	$8.38	+$1.98	$7.94	$20.82 billion	$22.97 billion
8/5/2026	Q2 2026	SDGR Schrodinger	-$0.4145	$0.08	+$0.4945	$0.08	$47.19 million	$58.89 million
8/4/2026	Q2 2026	PFE Pfizer	$0.6820	$0.77	+$0.0880	-$0.04	$14.40 billion	$15.03 billion
8/3/2026	Q2 2026	ON onsemi	$0.7150	$0.74	+$0.0250	$0.56	$1.59 billion	$1.60 billion
7/27/2026	Q2 2026	AZN Astrazeneca	$2.50	$2.63	+$0.13	$1.61	$15.44 billion	$15.38 billion
7/27/2026	Q2 2026	AZN Astrazeneca	$2.50	$2.63	+$0.13	$1.61	$15.44 billion	$15.38 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AZN Astrazeneca	$4.34	2.70%	+2.30%	64.87%	N/A
AZN Astrazeneca	$4.34	2.70%	+2.30%	64.87%	N/A
AZNCF AstraZeneca	$2.80	1.50%	N/A	343.14%	N/A
GSK GSK	$1.79	3.48%	-7.86%	55.94%	N/A
GSK GSK	$1.79	3.48%	-7.86%	55.94%	N/A
LLY Eli Lilly and Company	$6.92	0.57%	+15.18%	23.22%	11 Years
ON onsemi	N/A	N/A	N/A	N/A	N/A
PFE Pfizer	$1.72	6.41%	-13.20%	226.32%	16 Years
SDGR Schrodinger	N/A	N/A	N/A	N/A	N/A

Latest SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Dividends

Announcement	Company	Period	Amount	Yield	Ex-Dividend Date	Record Date	Payable Date
7/28/2026	GSK GSK	quarterly	$0.4515	3.36%	8/14/2026	8/14/2026	10/8/2026
7/28/2026	GSK GSK	quarterly	$0.4515	3.36%	8/14/2026	8/14/2026	10/8/2026
6/22/2026	LLY Eli Lilly and Company	quarterly	$1.73	0.63%	8/14/2026	8/14/2026	9/10/2026
6/24/2026	PFE Pfizer	quarterly	$0.43	7.01%	7/24/2026	7/24/2026	9/1/2026
1/1/2100	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025
1/1/2100	GSK GSK	quarterly	$0.4206	4.3%	8/15/2025	8/15/2025	10/9/2025

(Data available from 1/1/2013 forward)

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AZN Astrazeneca	0.47	0.89	0.67
AZN Astrazeneca	0.47	0.89	0.67
AZNCF AstraZeneca	N/A	N/A	N/A
GSK GSK	0.81	0.82	0.52
GSK GSK	0.81	0.82	0.52
LLY Eli Lilly and Company	1.41	1.35	1.00
ON onsemi	0.51	3.46	2.49
PFE Pfizer	0.71	1.27	0.96
SDGR Schrodinger	N/A	2.71	2.71

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AZN Astrazeneca	20.35%
AZN Astrazeneca	20.35%
AZNCF AstraZeneca	40.87%
GSK GSK	15.74%
GSK GSK	15.74%
LLY Eli Lilly and Company	82.53%
ON onsemi	97.70%
PFE Pfizer	68.36%
SDGR Schrodinger	79.05%

Insider Ownership

Company	Insider Ownership
AZN Astrazeneca	N/A
AZN Astrazeneca	N/A
AZNCF AstraZeneca	N/A
GSK GSK	10.00%
GSK GSK	10.00%
LLY Eli Lilly and Company	0.14%
ON onsemi	0.35%
PFE Pfizer	0.62%
SDGR Schrodinger	10.10%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AZN Astrazeneca	96,100	1.55 billion	N/A	N/A
AZN Astrazeneca	96,100	1.55 billion	N/A	N/A
AZNCF AstraZeneca	83,500	N/A	N/A	Not Optionable
GSK GSK	66,841	2.02 billion	1.82 billion	Optionable
GSK GSK	66,841	2.02 billion	1.82 billion	Optionable
LLY Eli Lilly and Company	50,000	941.36 million	940.04 million	Optionable
ON onsemi	22,670	389.31 million	387.95 million	Optionable
PFE Pfizer	75,000	5.70 billion	5.66 billion	Optionable
SDGR Schrodinger	790	73.82 million	66.37 million	Optionable

SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Headlines

Recent News About These Companies

Dimensional Fund Advisors LP Cuts Holdings in Schrodinger, Inc. $SDGR

August 10 at 3:28 AM | marketbeat.com

Schrodinger (NASDAQ:SDGR) Upgraded by Wall Street Zen to Hold Rating

August 8 at 1:49 AM | americanbankingnews.com

Schrodinger (NASDAQ:SDGR) Raised to "Hold" at Wall Street Zen

August 8 at 1:47 AM | marketbeat.com

Morgan Stanley Keeps Their Hold Rating on Schrodinger (SDGR)

August 7, 2026 | theglobeandmail.com

BMO Capital Reaffirms Their Buy Rating on Schrodinger (SDGR)

August 7, 2026 | theglobeandmail.com

Schrodinger, Inc. Earnings Call Highlights Growth Amid Shift

August 6, 2026 | tipranks.com

Schrödinger, Inc. 2026 Q2 - Results - Earnings Call Presentation

August 6, 2026 | seekingalpha.com

Schrödinger, Inc. (SDGR) Q2 2026 Earnings Call Transcript

August 6, 2026 | seekingalpha.com

Schrödinger (SDGR) Is Up 8.5% After AI Co‑Scientist Deal With BMS And Q2 Profitability Shift – Has The Bull Case Changed?

August 6, 2026 | finance.yahoo.com

Schrodinger Q2 Earnings Call Highlights

August 6, 2026 | marketbeat.com

Flash résultats (SDGR) : Schrodinger, Inc. publie un chiffre d'affaires de 58,9 millions de dollars au deuxième trimestre

August 5, 2026 | zonebourse.comZ

Schrodinger, Inc. (SDGR) Q2 Earnings and Revenues Top Estimates

August 5, 2026 | zacks.com

Schrodinger (NASDAQ:SDGR) Announces Quarterly Earnings Results

August 5, 2026 | marketbeat.com

Schrödinger Reports Second Quarter 2026 Financial Results

August 5, 2026 | businesswire.com

Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

August 5, 2026 | nz.finance.yahoo.com

Schrodinger: A Rare AI-Adjacent Disruptor Still Not Priced For It

August 3, 2026 | seekingalpha.com

Schrodinger, Inc. $SDGR Shares Sold by Lazard Asset Management LLC

August 3, 2026 | marketbeat.com

Schrodinger, Inc. (NASDAQ:SDGR) Receives Consensus Rating of "Hold" from Analysts

July 31, 2026 | americanbankingnews.com

Schrodinger, Inc. (NASDAQ:SDGR) Receives Consensus Recommendation of "Hold" from Analysts

July 31, 2026 | marketbeat.com

ADAR1 Capital Management LLC Takes Position in Schrodinger, Inc. $SDGR

July 30, 2026 | marketbeat.com

Schrodinger (SDGR) to Post Quarterly Earnings on Wednesday

July 29, 2026 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Company Descriptions

Astrazeneca NYSE:AZN

$160.74 -1.17 (-0.72%)

As of 10:51 AM Eastern

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca NYSE:AZN

$160.74 -1.17 (-0.72%)

As of 10:51 AM Eastern

AstraZeneca OTCMKTS:AZNCF

$187.10 +1.06 (+0.57%)

As of 08/7/2026

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

GSK NYSE:GSK

$51.42 -0.75 (-1.43%)

As of 10:51 AM Eastern

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D. The company offers shingles, meningitis, respiratory syncytial virus, flu, polio, influenza, and pandemic vaccines. It also provides medicines for HIV, oncology, respiratory/immunology, and other specialty medicine products, as well as inhaled medicines for asthma and chronic obstructive pulmonary disease, and antibiotics for infections. It has a collaboration agreement with CureVac to develop mRNA-based influenza vaccines, and with Wave Life Sciences and Elsie Biotechnologies, Inc for oligonucleotide platform development. The company was formerly known as GlaxoSmithKline plc and changed its name to GSK plc in May 2022. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.

GSK NYSE:GSK

$51.42 -0.75 (-1.43%)

As of 10:51 AM Eastern

Eli Lilly and Company NYSE:LLY

$1,222.54 -9.40 (-0.76%)

As of 10:51 AM Eastern

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana.

onsemi NASDAQ:ON

$81.69 +1.91 (+2.40%)

As of 10:51 AM Eastern

onsemi is engaged in disruptive innovations and also a supplier of power and analog semiconductors. The firm offers vehicle electrification and safety, sustainable energy grids, industrial automation, and 5G and cloud infrastructure, with a focus on automotive and industrial end-markets. It operates through the following segments: Power Solutions Group, Advanced Solutions Group, and Intelligent Sensing Group. The Power Solutions Group segment offers discrete, module, and semiconductor products that perform multiple application functions, including power switching, power conversion, signal conditioning, circuit protection, signal amplification, and voltage reference functions. The Advanced Solutions Group segment is involved in the designing and developing of analog, mixed-signal, advanced logic, ASSPs and ASICs, Wi-Fi and power solutions for a broad base of end-users in the automotive, consumer, computing, industrial, communications, medical and aerospace/defense markets. The Intelligent Sensing Group segment is focused on the designing and developing of CMOS and CCD image sensors, as well as proximity sensors, image signal processors, single photon detectors, inclu

Pfizer NYSE:PFE

$26.85 -0.20 (-0.75%)

As of 10:51 AM Eastern

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands. It also provides medicines and vaccines in various therapeutic areas, such as biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Litfulo, Velsipity, and Cibinqo brands; amyloidosis, hemophilia, endocrine diseases, and sickle cell disease under the Vyndaqel family, Oxbryta, BeneFIX, Somavert, Ngenla, and Genotropin brands; sterile injectable and anti-infective medicines under the Sulperazon, Medrol, Zavicefta, Zithromax, and Panzyga brands; and biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Inlyta, Bosulif, Mektovi, Padcev, Adcetris, Talzenna, Tukysa, Elrexfio, Tivdak, Lorbrena, and Braftovi brands. In addition, the company involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, individual provider offices, retail pharmacies, and integrated delivery systems. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Merck KGaA; and BioNTech SE. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Schrodinger NASDAQ:SDGR

$19.13 +0.36 (+1.91%)

As of 10:51 AM Eastern

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Earnings

Compare Dividends

Latest SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

SDGR, AZN, AZN, AZNCF, LLY, GSK, GSK, ON, and PFE Company Descriptions

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools